Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.3502
-0.0272 (-7.21%)
Oct 29, 2025, 4:00 PM EDT - Market closed
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,689,990
Market Cap
7.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2023 | 4 | -16 | -80.00% |
| Dec 31, 2022 | 20 | -1 | -4.76% |
| Dec 31, 2021 | 21 | 12 | 133.33% |
| Dec 31, 2020 | 9 | 5 | 125.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADIL News
- 12 days ago - Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - GlobeNewsWire
- 20 days ago - Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution - GlobeNewsWire
- 6 weeks ago - Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 - GlobeNewsWire